Nha Trang Vaccines And Biological Products JointStock Co
UUPCOM:BIO12,400.00
VND
-100.00
(-0.80%)
ISIN
VN000000BIO6
Return %
Stock
S&P 500
1Y
11.71
14.20
3Y
-45.85
81.12
5Y
-80.78
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Nha Trang Vietnam
- IPO Date
- Aug 30, 2018
- Website
- biopharco2.com.vn
- Similar Companies
- Business
- Nha Trang Vaccines and Biological Products Joint Stock Company (UPCoM: BIO), commonly known as BIOPHARCO, is a Vietnam-based pharmaceutical and biotechnology enterprise engaged in the research, manufacturing, marketing, and distribution of vaccines, medical serums, probiotics, and healthcare biological products. Established in 2001 as Vaccines and Biological Products Company No. 2 under the Vietnamese Ministry of Health and equitized into a joint-stock company in 2016, the company is headquartered in Nha Trang, Khanh Hoa Province, Vietnam. BIOPHARCO operates WHO-GMP-certified production facilities and serves domestic hospitals, medical prevention centers, pharmaceutical wholesalers, and retail pharmacy chains across Vietnam. The company operates through four primary product segments: Probiotics and Digestive Health Formulations, including live micro-organism supplements and gastrointestinal therapeutic products marketed under brands such as Biolac, Biosubtyl-II, Baci-Subti, Pro-Acidol Plus, EnteroGran, Enterogolds, Cali Lactylase, and Vibilac-II; Vaccines and Immunological Serums, comprising preventive and therapeutic biologicals targeting infectious diseases and clinical emergencies such as rabies, tetanus, typhoid, diphtheria, and snake envenomation; Oral Rehydration and Electrolyte Therapies, including oral rehydration salts and nutrient-fortified electrolyte powders sold under brands such as Oresol-II and ORS C Plus; and Functional Foods and Bioprocessing, which encompasses dietary wellness supplements, topical cosmetic formulations, and bulk microbial raw materials. In recent operational developments, BIOPHARCO has advanced the technological modernization of its WHO-GMP manufacturing infrastructure in Khanh Hoa Province to increase output capacity and satisfy upgraded national pharmaceutical quality standards. The company has also pursued strategic technology transfer agreements and research collaborations to introduce advanced microbial strains, enhance probiotic yield fermentation, and broaden its over-the-counter and preventive healthcare portfolio across nationwide distribution channels.